Opportunities for antimicrobial therapy of diseases accompanied by pathological discharge from the genital tract: results of the multicenter observational Prospectus program


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To study the etiological pattern of diseases accompanied by pathological discharge from the genital tract in reproductive-aged women and to evaluate the efficacy and tolerability of Macmiror Complex (nifuratel + nystatin) in the treatment of these diseases in in the context of modern clinical practice. Materials and methods: The prospective multicenter observational Prospectus program was implemented in 11 centers of 10 cities of the Russian Federation (Moscow, Saint Petersburg, Nizhny Novgorod, Voronezh, Stavropol, Kazan, Ufa, Novosibirsk, Yekaterinburg, and Vladivostok). To establish the etiology of diseases accompanied by pathological discharge from the genital tract, such as bacterial vaginosis, aerobic vaginitis, and vulvovaginal candidiasis, a molecular biological study was conducted using a procedure based on real-time PCR AmpliPrime-Floroscreen (NextBio LLC). The combined drug nifuratel + nystatin (Macmiror Complex, Polichem, Italy) as vaginal capsules was used for etiotropic therapy and the patients were followed up at 10, 30 and 90 days after the therapy. At 10-day follow-up, the clinical efficiency was evaluated using the clinical data (namely, relief of the signs and symptoms of the disease). Molecular biological control of the treatment was carried out at 30-day follow-ups. The drug’s tolerability (frequency of adverse events) and the number of relapses after a therapy cycle in the next three months were also analyzed. Results: The investigation enrolled 93 patients with the established etiology of diseases accompanied by pathological discharge from the genital tract by PCR using the AmpliPrime-Floroscreen tests. The patients’ mean age was 32.9±7.7years. The etiological pattern included diseases, such as bacterial vaginosis (35/93 (38%)), vulvovaginal candidiasis (21/93 (22%)), aerobic vaginitis (9/93 (10%)), and mixed vaginitis (28/93 (30%)). The clinical efficiency of the therapy was achieved in 94.6% of cases. During 3 months of follow-up, clinical relapses occurred in no more than 8.3% of cases. The molecular biological evaluation of the efficiency of treatment showed a positive result in 87.5% of cases. Excellent and good tolerances of Macmiror Complex were noted in 85.3% of cases; no allergic reactions were seen in 100% of cases. Conclusion: The pattern of diseases accompanied by pathological discharge from the genital tract exhibits a high proportion of mixed diseases. Macmiror Complex has demonstrated high eff iciency and good tolerance and therefore can be recommendedfor active clinical application in patients with diseases accompanied by pathological discharge from the genital tract, including mixed vaginitis.

Full Text

Restricted Access

About the authors

Inna A. Apolikhina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: i_apolikhina@oparina4.ru
Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation; Professor of the Department of Obstetrics, Gynecology, Perinatology and Reproductology

Alexander E. Guschin

Moscow Scientific and Practical Center for Dermatovenerology and Cosmetology, Moscow Department of Health

Email: aguschinl965@mail.ru
PhD. (Bio), Leading Researcher

Zulfia N. Efendieva

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: efendievaz@yandex.ru
Ph.D., obstetrician-gynecologist at the Department of Aesthetic Gynecology and Rehabilitation

Yuri A. Tyulenev

Moscow Scientific and Practical Center for Dermatovenerology and Cosmetology, Moscow Department of Health

Email: tulenevsk@gmail.com
PhD. (Bio), Junior Researcher at the Department of Anogenital Dermatoses and Sexually Transmitted Infections

References

  1. Sherrard J., Wilson J., Donders G., Mendling W., Jensen J.S. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organization (WHO) guideline on the management of vaginal discharge. Int. J. STD AIDS. 2018; 29(13): 1258-72. https://dx.doi.org/10.1177/0956462418785451.
  2. Lamont R.F., Morgan D.J., Wilden S.D., Taylor-Robinson D. Prevalence of bacterial vaginosis in women attending one of three general practices for routine cervical cytology. Int. J. STD AIDS. 2000; 11(8): 495-8. https://dx.doi.org/10.1258/0956462001916371.
  3. Mendling W., Mailland F. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Arzneimittelforschung. 2002; 52(1): 8-13. https://dx.doi.org/10.1055/s-0031-1299849.
  4. Бантьева М.Н., Суханова Л.П. Вопросы оптимизации амбулаторной акушерско-гинекологической службы. Социальные аспекты здоровья населения. Электронный научный журнал «Социальные аспекты здоровья населения». 2011; 3(19). Доступно по: http://vestnik.mednet.ru/content/view/309/30/lang,ru/ Дата обращения 07.12.2021.
  5. Mirmonsef P., Krass L., Landay A., Spear G.T. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curro HIV Res. 2012; 10(3): 202-10. https://dx.doi.org/10.2174/157016212800618165.
  6. Sobel J.D., Subramanian C., Foxman B., Fairfax M., Gygax S.E. Mixed vaginitis-more than coinfection and with therapeutic implications. Curr. Infect. Dis. Rep. 2013; 15(2): 104-8. https://dx.doi.org/10.1007/s11908-013-0325-5.
  7. Румянцева Т.А., Сурсяков С.А., Хайруллина Г.А., Чернышова Л.А., Гущин А.Е. Вагинальные выделения у пациенток гинекологического профиля: этиология и подходы к диагностике. Акушерство и гинекология. 2015; 8: 96-101.
  8. Schwiertz A., Taras D., Rusch K., Rusch V. Throwing the dice for the diagnosis of vaginal complaints? Ann. Clin. Microbiol. Antimicrob. 2006; 5: 4. https://dx.doi.org/10.1186/1476-0711-5-4.
  9. Verstraelen H., Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr. Opin. Infect. Dis. 2013; 26(1): 86-9. https://dx.doi.org/10.1097/QC0.0b013e32835c20cd.
  10. Unemo M., Bradshaw C.S., Hocking J.S., de Vries H.J.C., Francis S.C., Mabey D. et al. Sexually transmitted infections: challenges ahead. Lancet Infect. Dis. 2017; 17(8): e235-79. https://dx.doi.org/10.1016/S1473-3099(17)30310-9.
  11. Munoz-Barreno A., Cabezas-Mera F., Tejera E., Machado A. Comparative effectiveness of treatments for bacterial vaginosis: A network metaanalysis. Antibiotics (Basel). 2021; 10(8): 978. https://dx.doi.org/10.3390/antibiotics10080978.
  12. Sobel J.D., Schmitt C., Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J. Infect. Dis. 1993; 167(3): 783-4. https://dx.doi.org/https://dx.doi.org/10.1093/infdis/167.3.783.
  13. Bradshaw C.S., Morton A.N., Hocking J., Garland S.M., Morris M.B., Moss L.M. et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 2006; 193(11): 1478-86. https://dx.doi.org/10.1086/503780.
  14. Togni G., Battini V., Bulgheroni A., Mailland F., Caserini M., Mendling W. In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis? Antimicrob. Agents Chemother. 2011; 55(5): 2490-2. https://dx.doi.org/10.1128/AAC.01623-10.
  15. Бальмер Дж. и Группа мультицентрового исследования. Комбинация нифуратела и нистатина (Макмирор Комплекс) в лечении вульвовагинитов, вызванных смешанной грибковой, бактериальной и трихомонадой инфекцией. Медико-социальные проблемы семьи. 2012; 17(3-4): 30-3.
  16. Jahic M., Balic A., Nurkic M., Dragovic J., Adzajlic A., Habib ovic A. et al. Local combined therapy of vaginal infections by nifuratel-nistatin. Med. Glas (Zenica). 2010; 7(1): 86-8. (Croatian).
  17. Серов В.Н., Шаповаленко С.А. Микробиоценоз влагалища и инфекционные вульвовагиниты: выбор препарата для рациональной терапии. Вопросы гинекологии, акушерства и перинатологии 2004; 3(4): 27-31.
  18. Серов В.Н., Шаповаленко С.А. Рациональная терапия вульвовагинитов смешанной этиологии и профилактика рецидивов. РМЖ. 2003; 16: 946-50.
  19. Swidsinski A., Guschin A., Tang Q., Dorjfel Y., Verstraelen H., Tertychnyy A. et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am. J. Obstet. Gynecol. 2019; 220(1): 91. e1-91. e8. https://dx.doi.org/10.1016/j.ajog.2018.10.023.
  20. Ponde N.O., Lortal L., Ramage G., Naglik J.R., Richardson J.P. Candida albicans biofilms and polymicrobial interactions. Crit. Rev. Microbiol. 2021; 47(1): 91-111. https://dx.doi.org/10.1080/1040841X.2020.1843400.
  21. Obiero J., Rulisa S., Ogongo P., Wiysonge C.S. Nifuratel-Nystatin combination for the treatment of mixed infections of bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis. Cochrane Database Syst. Rev. 2018; (4): CD013012. https://dx.doi.org/10.1002/14651858.CD013012.
  22. Перламутров Ю.Н., Гомберг М.А., Чернова Н.И., Бочкова О.И., Щербо С.Н. Эффективность нифуратела и метронидазола в терапии бактериального вагиноза, ассоциированного с Atopobium vaginae. Вопросы гинекологии, акушерства и перинатологии. 2011; 10(3): 22-5.
  23. Российское общество акушеров-гинекологов. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.; 2019. 20c.
  24. Mendling W., Poli A., Magnani P. Clinical effects of nifuratel in vulvovaginal infections. A meta-analysis of metronidazole-controlled trials. Arzneimittelforschung. 2002; 52(10): 725-30. https://dx.doi.org/10.1055/0031-1299958.
  25. Liang Q., Li N., Song S., Zhang A., Li N., Duan Y. High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study. J. Obstet Gynaecol Res. 2016; 42(10): 1354-60. https://dx.doi.org/10.1111/jog.13052.
  26. Румянцева Т.А., Сурсяков В.А., Хайруллина Г.А., Чернышова Л.А., Гущин А.Е. Вагинальные выделения у пациенток гинекологического профиля: этиология и подходы к диагностике. Акушерство и гинекология. 2015. 8: 96-101.
  27. Доброхотова Ю.Э., Бондаренко К.Р., Гущин А.Е., Румянцева Т.А., Долгова Т.В., Кузнецов П.А., Джохадзе Л.С. Результаты исследования цервико-вагинальной микробиоты методом ПЦР в реальном времени у беременных с угрожающими преждевременными родами. Акушерство и гинекология. 2018. 11: 50-9. https://dx.doi.org/10.18565/aig.2018.11.50-59.
  28. Кира Е.Ф., Роговская С.И., Артымук Н.В., Савичева А.М., Гущин А.Е., Румянцева Т.А., Иванова О.В. Результаты изучения эффективности и безопасности вагинального применения орнидазола при лечении бактериального вагиноза. Акушерство и гинекология. 2015; 8: 89-95.
  29. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н., ред. Практическое руководство по антиинфекционной химиотерапии. Смоленск; 2007. 420c.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies